how many americans take glp 1 drugs The GLP-1 Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss America's Most Talked-About Drug Has

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease

Prescribing information (Amneal Pharmaceuticals, 2025)

We see Novo Nordisk and Eli Lilly as overvalued despite assuming that a quarter of US adults with obesity will be on GLP-1 therapies by 2031, leading to a GLP-1 market north of $200 billion in 2031, before generic semaglutide (Wegovy/Ozempic/Rybelsus) launches. Competition rises

Patience during verification and consistency in documentation requests are both normal and expected

Brand-name GLP-1 prices show no decline trajectory, and patents protect exclusivity through 20312033

H.ManjiH